Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates

Summary

Prophylaxis is the recommended treatment for children with severe haemophilia A, but whether prophylaxis should be continued in adulthood is still under debate. Previous studies with limited follow-up have suggested that some patients may be able to stop prophylaxis in adulthood, while maintaining good joint health. This single-centre observational cohort study examined patients with severe haemophilia A born 1970–1988 without inhibitor development, and assessed the long-term consequences of discontinuing prophylaxis. Patient-initiated changes in prophylaxis, including all switches to on-demand treatment lasting a minimum of two consecutive weeks, were recorded from the time self-infusion began until the last evaluation. Sixty-six patients were evaluated at a median age of 32.4 years: 26 of patients had stopped prophylaxis for a median of 10 years, 15 had interrupted prophylaxis and 59 had continued prophylaxis. Annual joint bleeding rate (AJBR), Haemophilia Joint Health Score (HJHS-2.1; 0–124 points), radiological Pettersson score (0–78 points) and Haemophilia Activities List score (HAL; 100–0 points) were compared between patients who stopped and patients who continued prophylaxis. Although self-reported bleeding rates and functional limitations were similar in both groups (AJBR: 1.5 vs 1.2 and HAL: 84 vs 84 for those who stopped and continued prophylaxis, respectively), objective assessment of joint status showed increased arthropathy after 10 years of on-demand treatment in patients who stopped prophylaxis compared with those who continued (HJHS: 23 vs. 14 and Pettersson: 16 vs 5, respectively; P< 0.01). These results support continuation of long-term prophylaxis in adults and demonstrate the need for objective monitoring of joint status.

Trial registration: Dutch Trial Registry number 3098; UTN U1111–1121–7069.

Keywords

Arthropathy - joint bleed - haemophilia - prophylaxis - X-rays

• References

• 1 Van Creveld S. Prophylaxis of joint hemorrhages in haemophilia. Acta Haematol 1971; 45: 120-127.
• 2 Nilsson IM, Berntorp E, Lofqvist T. et al. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
• 3 Srivastava A, Brewer AK, Mauser-Bunschoten EP. et al. Guidelines for the management of haemophilia. Haemophilia 2013; 19: e1-e47.
• 4 Van Dijk K, Fischer K, Van der Bom JG. et al. Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol 2005; 130: 107-112.
• 5 Richards M, Altisent C, Batorova A. et al. Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data. Haemophilia 2007; 13: 473-479.
• 6 Lindvall K, Colstrup L, Wollter IM. et al. Compliance with treatment and understanding of own disease in patients with severe and moderate haemophilia. Haemophilia 2006; 12: 47-51.
• 7 Fischer K, Van der Bom JG, Prejs R. et al. Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome. Haemophilia 2001; 7: 544-550.
• 8 Du Treil S, Rice J, Leissinger CA. Quantifying adherence to treatment and its relationship to quality of life in a well-characterized haemophilia population. Haemophilia 2007; 13: 493-501.
• 9 De Moerloose P, Urbancik W, Van den Berg H. M.. et al. A survey of adherence to haemophilia therapy in six European countries: results and recommendations. Haemophilia 2008; 14: 931-938.
• 10 Collins PW, Blanchette VS, Fischer K. et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe haemophilia A. J Thromb Haemost 2009; 7: 413-420.
• 11 Berntorp E, Astermark J, Bjorkman S. et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003; 9 (Suppl. 01) 1-4.
• 12 Richards M, Williams M, Chalmers E. et al. A United Kingdom Haemophilia Centre Doctors’ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol 2010; 149: 498-507.
• 13 Makris M. Prophylaxis in haemophilia should be life-long. Blood Transfus 2012; 10: 165-168.
• 14 Manco-Johnson MJ, Sanders J, Ewing N. et al. Consequences of switching from prophylactic treatment to on-demand treatment in late teens and early adults with severe haemophilia A: the TEEN/TWEN study. Haemophilia 2013; 19: 727-735.
• 15 Manco-Johnson MJ, Abshire TC, Shapiro AD. et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe haemophilia. N Engl J Med 2007; 357: 535-544.
• 16 Nederlandse Vereniging van Hemofiliebehandelaars (NVHB). Richtlijn Diagnostiek en behandeling van hemofilie en aanverwante hemostasestoornissen. 2009; pp. 68-69.
• 17 Van Genderen FR, Westers P, Heijnen L. et al. Measuring patients’ perceptions on their functional abilities: validation of the Haemophilia Activities List. Haemophilia 2006; 12: 36-46.
• 18 Van Genderen FR, Van Meeteren NL, Van der Bom JG. et al. Functional consequences of haemophilia in adults: the development of the Haemophilia Activities List. Haemophilia 2004; 10: 565-571.
• 19 Blanchette VS, Key NS, Ljung LR. et al. Definitions in haemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12: 1935-1939.
• 20 Hilliard P, Funk S, Zourikian N. et al. Haemophilia joint health score reliability study. Haemophilia 2006; 12: 518-525.
• 21 Creel GL, Light KE, Thigpen MT. Concurrent and construct validity of scores on the Timed Movement Battery. Phys Ther 2001; 81: 789-798.
• 22 Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980; 153-159.
• 23 De Moerloose P, Fischer K, Lambert T. et al. Recommendations for assessment, monitoring and follow-up of patients with haemophilia. Haemophilia 2012; 18: 319-325.
• 24 Fischer K, De Kleijn P. Using the Haemophilia Joint Health Score for assessment of teenagers and young adults: exploring reliability and validity. Haemophilia 2013; 19: 944-950.
• 25 Pettersson H, Nilsson IM, Hedner U. et al. Radiologic evaluation of prophylaxis in severe haemophilia. Acta Paediatr Scand 1981; 70: 565-570.
• 26 Fischer K, Steen Carlsson K, Petrini P. et al. Intermediate-dose versus high-dose prophylaxis for severe haemophilia: comparing outcome and costs since the 1970s. Blood 2013; 122: 1129-1136.
• 27 Fischer K, Ljung R, Platokouki H. et al. Prospective observational cohort studies for studying rare diseases: the European PedNet Haemophilia Registry. Haemophilia 2014; 20: e280-e286.
• 28 Schramm W, Royal S, Kroner B. et al. Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia 2002; 8: 33-43.
• 29 Van Dijk K, Fischer K, Van der Bom JG. et al. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia 2005; 11: 438-443.
• 30 Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-399.
• 31 Molho P, Rolland N, Lebrun T. et al. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. Haemophilia 2000; 6: 23-32.
• 32 Rainsford SG, Hall A. A three-year study of adolescent boys suffering from haemophilia and allied disorders. Br J Haematol 1973; 24: 539-551.
• 33 Astermark J, Petrini P, Tengborn L. et al. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109-1113.
• 34 Schwartz CE, Bode R, Repucci N. et al. The clinical significance of adaptation to changing health: a meta-analysis of response shift. Qual Life Res 2006; 15: 1533-1550.
• 35 Fischer K, Bom JG, Mauser-Bunschoten EP. et al. Effects of haemophilic arthropathy on health-related quality of life and socio-economic parameters. Haemophilia 2005; 11: 43-48.